Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (4): 295-298.doi: 10.35541/cjd.20210736
• Original Articles • Previous Articles Next Articles
Liu Bo, Song Xiaoting, Li Ruoyu, Zhao Zuotao
Received:
2021-10-09
Revised:
2022-02-13
Online:
2022-04-15
Published:
2022-04-01
Contact:
Zhao Zuotao
E-mail:zhaozuotaotao@163.com
Liu Bo, Song Xiaoting, Li Ruoyu, Zhao Zuotao. Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis[J]. Chinese Journal of Dermatology, 2022, 55(4): 295-298.doi:10.35541/cjd.20210736
[1] | Szymański U, Cios A, Ciepielak M, et al. Cytokines and apoptosis in atopic dermatitis[J]. Postepy Dermatol Alergol, 2021,38(2):1⁃13. doi: 10.5114/ada.2019.88394. |
[2] | Roesner LM, Heratizadeh A. Barrier defect in atopic dermatitis ⁃ possibilities and limits of basic skin therapy[J]. Allergol Select, 2021,5:287⁃292. doi: 10.5414/ALX02268E. |
[3] | Torres T, Ferreira EO, Gonçalo M, et al. Update on atopic dermatitis[J]. Acta Med Port, 2019,32(9):606⁃613. doi: 10. 20344/amp.11963. |
[4] | Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I[J]. J Eur Acad Dermatol Venereol, 2018,32(5):657⁃682. doi: 10.1111/jdv.14891. |
[5] | Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II[J]. J Eur Acad Dermatol Venereol, 2018,32(6):850⁃878. doi: 10.1111/jdv.14888. |
[6] | Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis[J]. Expert Rev Clin Pharmacol, 2018,11(5):467⁃474. doi: 10.1080/17512433.2018.1449642. |
[7] | Gooderham MJ, Hong HC, Eshtiaghi P, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis[J]. J Am Acad Dermatol, 2018,78(3 Suppl 1):S28⁃S36. doi: 10.1016/j.jaad.2017.12.022. |
[8] | Gandhi NA, Pirozzi G, Graham N. Commonality of the IL⁃4/IL⁃13 pathway in atopic diseases[J]. Expert Rev Clin Immunol, 2017,13(5):425⁃437. doi: 10.1080/1744666X.2017.1298443. |
[9] | Brunner PM, Guttman⁃Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad⁃spectrum and targeted therapies[J]. J Allergy Clin Immunol, 2017,139(4S):S65⁃S76. doi: 10.1016/j.jaci.2017.01.011. |
[10] | Bullens DM, Kasran A, Peng X, et al. Effects of anti⁃IL⁃4 receptor monoclonal antibody on in vitro T cell cytokine levels: IL⁃4 production by T cells from non⁃atopic donors[J]. Clin Exp Immunol, 1998,113(3):320⁃326. doi: 10.1046/j.1365⁃2249.1998. 00646.x. |
[11] | Kamata M, Tada Y. A literature review of real⁃world effectiveness and safety of dupilumab for atopic dermatitis[J]. JID Innov, 2021,1(3):100042. doi: 10.1016/j.xjidi.2021.100042. |
[12] | 顾建青, 高翔, 孙劲旅, 等. 度普利尤单抗治疗中重度特应性皮炎初步临床观察[J]. 中华临床免疫和变态反应杂志, 2021,15(4):370⁃375. doi: 10.3969∕j.issn.1673⁃8705.2021.04.003. |
[1] | . Analysis of clinicopathological features and prognosis of 163 cases of stage Ⅰ cutaneous melanoma [J]. Chinese Journal of Dermatology, 2022, 55(5): 389-394. |
[2] | Ye-Bei HU. Tranexamic acid for the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(5): 460-462. |
[3] | Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2021 [J]. Chinese Journal of Dermatology, 2022, 55(4): 369-372. |
[4] | Li Wei, Yin Huibin. Heterogeneity across skin sites in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 349-352. |
[5] | Tian Jing, Liang Yuan, Shen Chunping, Zhao Mutong, Wang Yang, Wang Shan, Jiao Lei, Ma Lin. Analysis of short-term efficacy and safety of the first subcutaneous injection of dupilumab in the treatment of moderate-to-severe childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 299-303. |
[6] | Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Group on Children, Chinese Society of Dermatology. Expert consensus on clinical application of wet-wrap therapy for atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 289-294. |
[7] | Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767. |
[8] | Wang Yue, Yan Yulin. Analysis of adverse drug reactions and reasons for drug discontinuation during acitretin therapy in 171 patients with psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(3): 242-245. |
[9] | Li Hao, Wang Li, Han Xianwei, Sun Tong, Su Fang, Sun Xiaodong, Han Ying, Yang Guoling, Liu Xiaoming, Wang Kaibo. Analysis of clinical characteristics of bullous pemphigoid developing after the treatment with dipeptidyl peptidase-Ⅳ inhibitors in 32 patients with diabetes mellitus [J]. Chinese Journal of Dermatology, 2022, 55(3): 213-218. |
[10] | Liu Yuzhen, Zeng Rong, Zheng Nana, Duan Zhimin, Xu Haoxiang, Wu Qiuju, Lin Tong, Li Min. Effect of different incubation time of aminolevulinic acid on photodynamic inhibition of Propionibacterium acnes biofilms [J]. Chinese Journal of Dermatology, 2022, 55(3): 208-212. |
[11] | Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2022) [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195. |
[12] | Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275. |
[13] | Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156. |
[14] | Zhang Tingting, Zhu Fengyi, Yang Mei, Zhang Ping, Xia Ping, Zhou Xiaoyong. Clinical efficacy and safety of secukinumab in the treatment of 7 cases of erythrodermic psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210644-e20210644. |
[15] | Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210694-e20210694. |
|